相似文献
1
Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer.
Neoplasia. 2006 Dec;8(12):1083-9. doi: 10.1593/neo.06421.
2
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Mod Pathol. 2002 Jan;15(1):35-44. doi: 10.1038/modpathol.3880487.
3
Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.
Proteomics. 2008 Dec;8(23-24):5038-52. doi: 10.1002/pmic.200800303.
4
High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.
J Mol Diagn. 2016 Jan;18(1):131-43. doi: 10.1016/j.jmoldx.2015.08.004. Epub 2015 Nov 20.
5
Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.
Mol Cancer Res. 2014 Feb;12(2):250-63. doi: 10.1158/1541-7786.MCR-13-0230. Epub 2013 Dec 13.
6
Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer.
BJU Int. 2004 Aug;94(3):407-11. doi: 10.1111/j.1464-410X.2004.04829.x.
7
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Lab Invest. 1997 Nov;77(5):437-48.
8
Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.
Eur J Hum Genet. 2010 May;18(5):560-8. doi: 10.1038/ejhg.2009.230. Epub 2010 Jan 6.
9
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047.
10
Breast cancer metastases are molecularly distinct from their primary tumors.
Oncogene. 2008 Apr 3;27(15):2148-58. doi: 10.1038/sj.onc.1210858. Epub 2007 Oct 22.
引用本文的文献
1
Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection.
Int Urol Nephrol. 2021 Oct;53(10):2027-2039. doi: 10.1007/s11255-021-02938-z. Epub 2021 Jul 6.
2
The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells.
Mol Oncol. 2020 Dec;14(12):3100-3120. doi: 10.1002/1878-0261.12818. Epub 2020 Oct 23.
3
Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy.
Ther Adv Urol. 2020 Jun 24;12:1756287220929481. doi: 10.1177/1756287220929481. eCollection 2020 Jan-Dec.
4
High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection.
Asian J Androl. 2020 May-Jun;22(3):323-329. doi: 10.4103/aja.aja_70_19.
5
Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease.
PLoS One. 2014 Apr 14;9(4):e94476. doi: 10.1371/journal.pone.0094476. eCollection 2014.
6
Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.
Cancer Microenviron. 2013 Dec;6(3):213-30. doi: 10.1007/s12307-013-0138-y. Epub 2013 Nov 10.
7
Identification of ovarian cancer metastatic miRNAs.
PLoS One. 2013;8(3):e58226. doi: 10.1371/journal.pone.0058226. Epub 2013 Mar 12.
8
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells.
Nat Commun. 2013;4:1623. doi: 10.1038/ncomms2627.
9
Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.
Genes Cancer. 2012 Feb;3(2):87-101. doi: 10.1177/1947601912456287.
10
ERG rearrangement metastasis patterns in locally advanced prostate cancer.
Urology. 2010 Apr;75(4):762-7. doi: 10.1016/j.urology.2009.10.010.
本文引用的文献
1
Preliminary evaluation of prostate cancer metastatic risk biomarkers.
Int J Biol Markers. 2005 Jul-Sep;20(3):141-5. doi: 10.1177/172460080502000301.
2
Evolution of 8p loss in transformed human prostate epithelial cells.
Cancer Genet Cytogenet. 2004 Oct 1;154(1):36-43. doi: 10.1016/j.cancergencyto.2004.02.013.
3
Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer.
BJU Int. 2004 Aug;94(3):407-11. doi: 10.1111/j.1464-410X.2004.04829.x.
4
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.
J Clin Oncol. 2004 Jul 15;22(14):2790-9. doi: 10.1200/JCO.2004.05.158.
5
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
Cancer Res. 2004 Jun 1;64(11):3814-22. doi: 10.1158/0008-5472.CAN-03-3881.
6
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.
Hum Mol Genet. 2004 Jul 1;13(13):1303-13. doi: 10.1093/hmg/ddh155. Epub 2004 May 11.
7
Cancer statistics, 2004.
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8.
8
Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6. doi: 10.1073/pnas.0304146101. Epub 2004 Jan 7.
9
High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity.
Oncogene. 2003 May 8;22(18):2739-49. doi: 10.1038/sj.onc.1206341.
10
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays.
Am J Pathol. 2003 Mar;162(3):763-70. doi: 10.1016/S0002-9440(10)63873-4.
Zotero 插件